Endologix Company Profile (NASDAQ:ELGX)

About Endologix (NASDAQ:ELGX)

Endologix logoEndologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Devices & Implants
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:ELGX
  • CUSIP: 29266S10
  • Web: www.endologix.com
  • Market Cap: $357.93 million
  • Outstanding Shares: 83,434,000
Average Prices:
  • 50 Day Moving Avg: $4.36
  • 200 Day Moving Avg: $5.50
  • 52 Week Range: $4.08 - $13.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.94
  • P/E Growth: -0.20
Sales & Book Value:
  • Annual Revenue: $190.75 million
  • Price / Sales: 1.88
  • Book Value: $1.16 per share
  • Price / Book: 3.70
  • EBIDTA: ($54,380,000.00)
  • Net Margins: -40.77%
  • Return on Equity: -46.32%
  • Return on Assets: -13.67%
  • Debt-to-Equity Ratio: 2.28%
  • Current Ratio: 2.82%
  • Quick Ratio: 2.12%
  • Average Volume: 754,070 shs.
  • Beta: 0.68
  • Short Ratio: 30.56

Frequently Asked Questions for Endologix (NASDAQ:ELGX)

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) released its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.08. The firm earned $48.60 million during the quarter, compared to analyst estimates of $47.58 million. Endologix had a negative net margin of 40.77% and a negative return on equity of 46.32%. The business's revenue for the quarter was down 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.20) EPS. View Endologix's Earnings History.

When will Endologix make its next earnings announcement?

Endologix is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Endologix.

Where is Endologix's stock going? Where will Endologix's stock price be in 2017?

10 equities research analysts have issued 12-month target prices for Endologix's stock. Their forecasts range from $5.00 to $10.00. On average, they expect Endologix's stock price to reach $6.33 in the next twelve months. View Analyst Ratings for Endologix.

What are analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:

  • 1. Canaccord Genuity analysts commented, "Alimera reported 2Q17 Iluvien US sales of $8.1M which was above our estimate of." (8/4/2017)
  • 2. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (7/25/2017)

Who are some of Endologix's key competitors?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:

  • Daniel T. Lemaitre, Chairman of the Board
  • Robert D. Mitchell, President
  • John D. McDermott, Chief Executive Officer, Director
  • Vaseem Mahboob, Chief Financial Officer, Corporate Secretary
  • Michael V. Chobotov Ph.D., Chief Technology Officer
  • David M. Jennings, Vice President - Human Resources
  • Amanda L. DePalma, Vice President - Global Marketing
  • Meredith O. Huetter, Vice President - Global Medical Affairs
  • Michael P. Maszy, Vice President - Manufacturing
  • Laura Nagel, Vice President - Global Quality

Who owns Endologix stock?

Endologix's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.96%), Redmile Group LLC (7.63%), NEA Management Company LLC (3.00%), Elk Creek Partners LLC (2.50%), State Street Corp (2.34%) and New York State Common Retirement Fund (1.46%). Company insiders that own Endologix stock include Amanda L Depalma, Charles Steele Love, Dan Lemaitre, Gregory D Waller, Guido J Neels, James Edward Machek, John D Mcdermott, Jose A Lima, Joseph A Dejohn, Michael V Chobotov, Robert D Mitchell, Thomas F Zenty III, Todd Abraham and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.

Who sold Endologix stock? Who is selling Endologix stock?

Endologix's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Elk Creek Partners LLC, Stoneridge Investment Partners LLC, New York State Common Retirement Fund, Ameriprise Financial Inc., FIL Ltd, JPMorgan Chase & Co. and C WorldWide Group Holding A S. View Insider Buying and Selling for Endologix.

Who bought Endologix stock? Who is buying Endologix stock?

Endologix's stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Vanguard Group Inc., State Street Corp, Marshall Wace North America L.P., TIAA CREF Investment Management LLC, Accredited Investors Inc., Stephens Inc. AR and Teachers Advisors LLC. Company insiders that have bought Endologix stock in the last two years include Dan Lemaitre, Guido J Neels, John D Mcdermott, Robert D Mitchell, Thomas F Zenty III, Todd Abraham and Vaseem Mahboob. View Insider Buying and Selling for Endologix.

How do I buy Endologix stock?

Shares of Endologix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of Endologix stock can currently be purchased for approximately $4.29.

MarketBeat Community Rating for Endologix (NASDAQ ELGX)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  279 (Vote Outperform)
Underperform Votes:  280 (Vote Underperform)
Total Votes:  559
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Endologix (NASDAQ:ELGX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 10 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $6.33 (47.63% upside)

Analysts' Ratings History for Endologix (NASDAQ:ELGX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/4/2017Canaccord GenuityReiterated RatingHoldMediumView Rating Details
8/3/2017Oppenheimer Holdings, Inc.Set Price TargetHold$5.00HighView Rating Details
8/2/2017Stifel NicolausSet Price TargetHold$6.00HighView Rating Details
7/31/2017Royal Bank Of CanadaReiterated RatingHold$5.00MediumView Rating Details
5/18/2017BMO Capital MarketsReiterated RatingHold$5.00HighView Rating Details
5/18/2017StephensDowngradeOverweight -> Equal Weight$6.00HighView Rating Details
5/18/2017BTIG ResearchDowngradeBuy -> Neutral$7.00HighView Rating Details
12/7/2016Leerink SwannReiterated RatingMarket Perform$11.00 -> $8.00N/AView Rating Details
12/4/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$14.00 -> $10.00N/AView Rating Details
11/16/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
8/3/2016Piper Jaffray CompaniesReiterated RatingOverweight$15.00N/AView Rating Details
2/22/2016Credit Suisse GroupLower Price TargetOutperform$16.00 -> $10.00N/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Endologix (NASDAQ:ELGX)
Earnings by Quarter for Endologix (NASDAQ:ELGX)
Earnings History by Quarter for Endologix (NASDAQ ELGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017($0.14)N/AView Earnings Details
8/2/2017Q2 2017($0.18)($0.10)$47.58 million$48.60 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.24)($0.18)$41.15 million$42.60 millionViewListenView Earnings Details
2/22/2017Q4 2016($0.19)($0.22)$48.69 million$47.46 millionViewListenView Earnings Details
11/1/2016Q316($0.15)($0.11)$51.83 million$52.12 millionViewN/AView Earnings Details
8/2/2016Q2($0.20)($0.20)$46.30 million$51.00 millionViewListenView Earnings Details
5/9/2016Q1($0.24)($0.25)$38.78 million$42.40 millionViewN/AView Earnings Details
2/22/2016Q4($0.16)($0.08)$39.97 million$39.20 millionViewListenView Earnings Details
10/26/2015Q315($0.14)($0.13)$38.12 million$38.20 millionViewListenView Earnings Details
8/3/2015Q215($0.13)($0.18)$39.47 million$39.50 millionViewN/AView Earnings Details
4/29/2015Q115($0.13)($0.14)$37.94 million$36.70 millionViewN/AView Earnings Details
2/25/2015Q414($0.10)($0.11)$38.10 million$38.80 millionViewN/AView Earnings Details
10/30/2014Q314($0.13)($0.13)$37.00 million$37.20 millionViewListenView Earnings Details
7/30/2014Q214($0.08)($0.06)$36.50 million$38.30 millionViewListenView Earnings Details
4/30/2014Q114($0.08)($0.08)$32.24 million$33.30 millionViewListenView Earnings Details
2/27/2014Q413($0.05)($0.05)$35.80 million$35.25 millionViewListenView Earnings Details
10/30/2013Q313($0.05)$0.01$32.47 million$33.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.06)($0.03)$33.94 million$34.00 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)($0.15)$29.26 million$29.80 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.03)($0.09)$29.03 million$29.22 millionViewN/AView Earnings Details
10/25/2012($0.04)($0.03)ViewN/AView Earnings Details
7/26/2012($0.04)($0.09)ViewN/AView Earnings Details
4/26/2012($0.06)($0.07)ViewN/AView Earnings Details
2/22/2012($0.05)($0.06)ViewN/AView Earnings Details
10/27/2011($0.05)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Endologix (NASDAQ:ELGX)
2017 EPS Consensus Estimate: ($0.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.22)($0.22)
Q2 20172($0.18)($0.16)($0.17)
Q3 20172($0.16)($0.15)($0.16)
Q4 20172($0.17)($0.13)($0.15)
(Data provided by Zacks Investment Research)


Dividend History for Endologix (NASDAQ:ELGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Endologix (NASDAQ:ELGX)
Insider Ownership Percentage: 4.10%
Insider Trades by Quarter for Endologix (NASDAQ:ELGX)
Institutional Ownership by Quarter for Endologix (NASDAQ:ELGX)
Insider Trades by Quarter for Endologix (NASDAQ:ELGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Dan LemaitreDirectorBuy22,522$4.43$99,772.46View SEC Filing  
5/19/2017Guido J NeelsDirectorBuy20,000$4.32$86,400.00View SEC Filing  
5/19/2017Robert D MitchellPresidentBuy2,200$4.32$9,504.00View SEC Filing  
12/14/2016John D McdermottCEOBuy10,000$6.67$66,700.00View SEC Filing  
12/14/2016Thomas F Zenty IIIDirectorBuy3,000$6.51$19,530.00View SEC Filing  
12/13/2016Vaseem MahboobCFOBuy20,000$6.25$125,000.00View SEC Filing  
11/18/2016Guido J NeelsDirectorBuy13,000$7.69$99,970.00View SEC Filing  
8/19/2016Jose A LimaVPSell4,710$11.68$55,012.80View SEC Filing  
8/5/2016Michael V ChobotovInsiderSell14,000$12.40$173,600.00View SEC Filing  
6/3/2016Gregory D WallerDirectorSell7,800$12.86$100,308.00View SEC Filing  
6/1/2016Amanda L DepalmaVPSell689$12.55$8,646.95View SEC Filing  
6/1/2016John D McdermottCEOSell6,116$12.55$76,755.80View SEC Filing  
6/1/2016Joseph A DejohnInsiderSell957$12.55$12,010.35View SEC Filing  
6/1/2016Robert D MitchellPresidentSell2,294$12.55$28,789.70View SEC Filing  
5/26/2016James Edward MachekVPSell6,500$12.76$82,940.00View SEC Filing  
1/26/2016Charles Steele LoveVPSell4,280$7.72$33,041.60View SEC Filing  
11/3/2015Guido J NeelsDirectorBuy11,000$9.32$102,520.00View SEC Filing  
11/3/2015Todd AbrahamVPBuy2,500$8.85$22,125.00View SEC Filing  
11/2/2015John D McdermottCEOBuy20,000$8.90$178,000.00View SEC Filing  
9/3/2015Jose A LimaVPSell1,923$12.60$24,229.80View SEC Filing  
5/26/2015Thomas WilderDirectorSell3,790$16.08$60,943.20View SEC Filing  
5/20/2015Jose A LimaVPSell1,872$16.75$31,356.00View SEC Filing  
4/6/2015Robert D MitchellPresidentSell45,000$17.33$779,850.00View SEC Filing  
12/12/2014Charles Steele LoveVPSell10,000$13.95$139,500.00View SEC Filing  
11/18/2014Charles Steele LoveVPBuy2,000$11.70$23,400.00View SEC Filing  
11/4/2014Guido J NeelsDirectorBuy10,000$11.21$112,100.00View SEC Filing  
11/4/2014John D McdermottCEOBuy25,000$11.25$281,250.00View SEC Filing  
8/4/2014Thomas WilderDirectorSell3,500$13.68$47,880.00View SEC Filing  
6/12/2014Robert D MitchellPresidentSell18,271$14.23$259,996.33View SEC Filing  
6/10/2014Robert D MitchellPresidentSell8,516$14.20$120,927.20View SEC Filing  
8/14/2013Stefan SchreckVPSell25,000$16.18$404,500.00View SEC Filing  
8/13/2013Stefan SchreckVPSell29,000$15.88$460,520.00View SEC Filing  
8/5/2013Gary SorsherVPSell12,483$15.98$199,478.34View SEC Filing  
8/5/2013John McdermottCEOSell165,000$16.00$2,640,000.00View SEC Filing  
8/2/2013Todd AbrahamVPSell9,994$15.90$158,904.60View SEC Filing  
8/1/2013John D McdermottCEOSell15,000$15.83$237,450.00View SEC Filing  
6/3/2013Thomas WilderDirectorSell22,500$13.25$298,125.00View SEC Filing  
5/28/2013Leonard M GreensteinVPSell1,253$14.01$17,554.53View SEC Filing  
12/28/2012Robert John KristCFOSell37,530$14.06$527,671.80View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Endologix (NASDAQ:ELGX)
Latest Headlines for Endologix (NASDAQ:ELGX)
businesswire.com logoLombard Medical Appoints Jonathan Hornsby as Vice President, Sales & Marketing
www.businesswire.com - September 20 at 4:15 AM
americanbankingnews.com logoEndologix, Inc. (ELGX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 16 at 2:46 AM
finance.yahoo.com logoIs There Now An Opportunity In Endologix Inc (ELGX)?
finance.yahoo.com - September 14 at 12:38 AM
bizjournals.com logoHealthcare Stock Performance Review -- Glaukos, Endologix, Merit Medical Systems, and HTG Molecular Diagnostics
www.bizjournals.com - September 12 at 7:00 PM
streetinsider.com logoEndologix (ELGX) Reports Collaboration Agreements with Japan Lifeline for Development & Commercialization of ... - StreetInsider.com
www.streetinsider.com - September 11 at 11:52 PM
finance.yahoo.com logoEndologix Announces Collaboration Agreements with Japan Lifeline for the Development and Commercialization of Thoracic Endovascular Systems in Japan
finance.yahoo.com - September 11 at 6:51 PM
americanbankingnews.com logo Analysts Expect Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $47.24 Million
www.americanbankingnews.com - September 6 at 3:32 AM
americanbankingnews.com logoEndologix, Inc. (ELGX) Expected to Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - September 4 at 6:22 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Downgraded by ValuEngine
www.americanbankingnews.com - September 3 at 2:04 PM
businesswire.com logoNeuros Medical Appoints Tom Wilder as President and CEO
www.businesswire.com - August 28 at 5:58 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 22 at 2:32 AM
americanbankingnews.com logoSmith & Nephew SNATS (SNN) versus Endologix (ELGX) Financial Comparison
www.americanbankingnews.com - August 21 at 10:22 PM
streetinsider.com logoEndologix (ELGX) Reports Positive Results from LEOPARD Clinical Study
www.streetinsider.com - August 19 at 5:18 PM
streetinsider.com logoEndologix (ELGX) Reports Positive Results from LEOPARD Clinical Study - StreetInsider.com
www.streetinsider.com - August 18 at 12:28 AM
finance.yahoo.com logoEndologix Announces Positive Clinical Results from the LEOPARD Clinical Study
finance.yahoo.com - August 17 at 7:27 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Expected to Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - August 17 at 8:48 AM
seekingalpha.com logoEndologix AFX/AFX2 endografts edge out rivals in head-to-head study; shares ahead 1% premarket
seekingalpha.com - August 17 at 8:47 AM
finance.yahoo.com logoEndologix, Inc. – Value Analysis (NASDAQ:ELGX) : August 15, 2017
finance.yahoo.com - August 15 at 6:54 PM
finance.yahoo.com logo3 Stocks Hitting 52-Week Lows: Time to Go Bargain Shopping?
finance.yahoo.com - August 7 at 6:31 PM
americanbankingnews.com logoLeerink Swann Research Analysts Lower Earnings Estimates for Endologix, Inc. (ELGX)
www.americanbankingnews.com - August 7 at 7:08 AM
americanbankingnews.com logoEndologix, Inc. (NASDAQ:ELGX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - August 6 at 11:20 AM
americanbankingnews.com logoEndologix, Inc. (NASDAQ:ELGX) Given Hold Rating at Canaccord Genuity
www.americanbankingnews.com - August 4 at 1:48 PM
americanbankingnews.com logoOppenheimer Holdings, Inc. Analysts Give Endologix, Inc. (ELGX) a $5.00 Price Target
www.americanbankingnews.com - August 3 at 6:38 PM
seekingalpha.com logoEndologix's (ELGX) CEO John McDermott on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 3 at 4:53 PM
finance.yahoo.com logoEdited Transcript of ELGX earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 5:11 AM
americanbankingnews.com logoEndologix, Inc. (NASDAQ:ELGX) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 2 at 10:52 PM
businesswire.com logoEndologix Reports Second Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - August 2 at 7:07 PM
finance.yahoo.com logoInvestor Network: Endologix, Inc. to Host Earnings Call
finance.yahoo.com - August 2 at 7:06 PM
finance.yahoo.com logoEndologix Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 7:06 PM
finance.yahoo.com logoEndologix reports 2Q loss
finance.yahoo.com - August 2 at 7:06 PM
finance.yahoo.com logoEndologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : August 1, 2017
finance.yahoo.com - August 1 at 6:53 PM
americanbankingnews.com logoEndologix, Inc. (ELGX) Expected to Announce Quarterly Sales of $47.67 Million
www.americanbankingnews.com - August 1 at 9:14 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Endologix, Inc. (NASDAQ:ELGX) to Post -$0.19 EPS
www.americanbankingnews.com - July 30 at 7:26 AM
americanbankingnews.com logoEndologix, Inc. (NASDAQ:ELGX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 28 at 10:03 AM
americanbankingnews.com logoEndologix, Inc. (NASDAQ:ELGX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 25 at 10:10 PM
americanbankingnews.com logoSt Jude Medical (STJ) versus Endologix (NASDAQ:ELGX) Head-To-Head Survey
www.americanbankingnews.com - July 25 at 12:28 AM
americanbankingnews.com logoEndologix, Inc. (ELGX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - July 24 at 10:56 PM
businesswire.com logoRobbins Arroyo LLP Is Investigating the Officers and Directors of Endologix, Inc. (ELGX) on Behalf of Shareholders - Business Wire (press release)
www.businesswire.com - July 21 at 8:07 PM
americanbankingnews.com logoReviewing Endologix (ELGX) & Glaukos Corporation (GKOS)
www.americanbankingnews.com - July 19 at 12:24 PM
businesswire.com logoEndologix, Inc. to Announce Second Quarter 2017 Financial Results on August 2, 2017 - Business Wire (press release)
www.businesswire.com - July 14 at 5:38 AM
finance.yahoo.com logoEndologix, Inc. to Announce Second Quarter 2017 Financial Results on August 2, 2017
finance.yahoo.com - July 12 at 6:51 PM
businesswire.com logoEndologix, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference - Business Wire (press release)
www.businesswire.com - July 10 at 11:11 PM
finance.yahoo.com logoEndologix, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - July 10 at 6:08 PM
americanbankingnews.com logo Brokerages Expect Endologix, Inc. (NASDAQ:ELGX) Will Announce Quarterly Sales of $47.67 Million
www.americanbankingnews.com - July 7 at 11:16 AM
americanbankingnews.com logoZacks: Analysts Anticipate Endologix, Inc. (NASDAQ:ELGX) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - July 5 at 10:18 PM
americanbankingnews.com logoEndologix (NASDAQ:ELGX) & Second Sight Medical Products (EYES) Head to Head Contrast
www.americanbankingnews.com - July 4 at 8:25 AM
prnewswire.com logoLifshitz & Miller LLP Announces Investigation of Aaron's, Inc., Axiom ... - PR Newswire (press release)
www.prnewswire.com - July 4 at 4:10 AM
americanbankingnews.com logoEndologix, Inc. (NASDAQ:ELGX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 3 at 10:16 AM
americanbankingnews.com logoReviewing Endologix (ELGX) & Stryker Corporation (SYK)
www.americanbankingnews.com - June 25 at 8:06 PM
prnewswire.com logoMedical Supplies Stocks on Investors' Radar -- Endologix, Microbot ... - PR Newswire (press release)
www.prnewswire.com - June 21 at 6:28 PM



Endologix (ELGX) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff